BELL
NEUTRALBelluscura Announces Strategic Review and Proposed Fundraising
The medical device company has initiated a strategic review and announced a proposed fundraising to strengthen its capital position and support growth prospects.
Belluscura
0.7500GBX
3.45%
Market Cap
3.01M
Volume
4.27M
98% of avg
P/E Ratio
EPS (TTM)
0
Beta
0.71
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.7500p18.0000p
0.7500p
BELL
NEUTRALBelluscura Plc Announces Holding(s) in Company Change
The healthcare company has announced a change in its major shareholding.
BELL
NEUTRALBelluscura Plc Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
BELL
NEUTRALBelluscura Provides Update on Recent Share Price Movement
The medical device company issues a statement addressing recent fluctuations in its share price, with no new updates on its business performance or outlook.
BELL
NEUTRALBelluscura Initiates Strategic Review to Address Funding Needs
The medical device company is launching a strategic review to address its funding needs, as it faces product sourcing challenges and seeks to strengthen its capital position.
BELL
GOODBelluscura Reports Strong Q1 Sales, Launches New Portable Oxygen Concentrator
The medical device developer reports a substantial increase in Q1 sales and the launch of a new portable oxygen concentrator, despite some tariff-related challenges.
BELL
NEUTRALBelluscura Announces Director Shareholding Change
The healthcare company has announced a change in director shareholding.
BELL
NEUTRALBelluscura Announces Change in Shareholding
The healthcare company has announced a change in its shareholding structure.
BELL
NEUTRALBelluscura Announces Change in Major Shareholding
The medical device company reports a change in major shareholding, with no significant implications.
BELL
NEUTRALBelluscura Announces Change in Major Shareholding
The medical device company has announced a change in major shareholding, with Dowgate Group Limited reducing its stake in the business.